Merck & Company Inc (MRK)
Merck & Co., Inc. is a global healthcare company focused on pharmaceuticals and animal health. In human health, its portfolio includes treatments and vaccines across oncology, infectious disease, cardiometabolic conditions, respiratory care, and other therapeutic areas, with products marketed under names such as Keytruda, Gardasil, Januvia, and Bridion. The company also has a veterinary business that supplies livestock and companion animal products, along with related health management solutions and services. Merck also participates in several collaboration and licensing arrangements, including agreements with Daiichi Sankyo, AstraZeneca, LaNova, Eisai, Bayer, Ridgeback Biotherapeutics, and Moderna. Founded in 1891, the company is headquartered in Rahway, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-MRK
|
$148.07
|
18.1% Upside
|
Undervalued
|
$134.04
|
6.9% Upside
|
Fair
|
Great
|
—
|
—
|
3.4
|
2.7%
|
August 4, 2026
|
34.6x
|
6.7x
|
4.7x
|
307.2 B
|
352.3 B
|
13.8%
|
99.8%
|
5.3
|
92.1%
|
158.0%
|
